US 12,448,630 B2
CRISPR-Cas systems and uses thereof
Bohong Chen, Guangzhou (CN); Yang Hu, Guangzhou (CN); Yulin Yu, Guangzhou (CN); Wenqiong Tan, Guangzhou (CN); Shaoyun Lin, Guangzhou (CN); Wenchang Xu, Guangzhou (CN); Youyu Wu, Guangzhou (CN); Xiaojie Ma, Guangzhou (CN); Jiajun Yu, Guangzhou (CN); and Jinshuai Sun, Guangzhou (CN)
Assigned to Lumiere Therapeutics Co., Ltd., Jiangsu (CN)
Filed by Lumiere Therapeutics Co., Ltd., Jiangsu (CN)
Filed on Aug. 30, 2024, as Appl. No. 18/820,460.
Claims priority of application No. 202311464815.0 (CN), filed on Nov. 6, 2023.
Prior Publication US 2025/0146023 A1, May 8, 2025
Int. Cl. C12N 9/22 (2006.01); C12N 9/78 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01)
CPC C12N 15/90 (2013.01) [C12N 9/22 (2013.01); C12N 9/78 (2013.01); C12N 15/11 (2013.01); C12Y 305/04004 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01)] 54 Claims
 
1. An engineered chimeric Cas12i polypeptide, wherein the engineered chimeric Cas12i polypeptide is capable of binding to a nucleic acid, and wherein the engineered chimeric Cas12i polypeptide comprises, from N-terminus to C-terminus, a first peptide segment, a second peptide segment, and a third peptide segment connected in sequence, wherein:
the first peptide segment comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of aa 1 to 897 of SEQ ID NO: 1 or aa 1 to 895 of SEQ ID NO: 3;
the second peptide segment comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs: 67 to 72; and
the third peptide segment comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of aa 1008 to 1044 of SEQ ID NO: 1 or aa 1016 to 1054 of SEQ ID NO: 3.